SITC's Cancer Immunotherapy Guidelines program is a collection of Clinical Practice Guidelines (CPGs) developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics. The SITC Lymphoma CPG was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. This CPG will provide recommendations regarding FDA-approved immunotherapies for Hodkin lymphoma and multiple subtypes of non-Hodgkin lymphoma, including rituximab, brentuximab vedotin and axicabtagene ciloleucel, as well as discussion of promising emerging treatment modalities and patient quality of life issues.
Published December 24, 2020 in the Journal for ImmunoTherapy of Cancer (JITC) as the "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma"
This advanced webinar is designed for attendees to learn and understand important immune checkpoint inhibitor-related adverse event-specific considerations for immunotherapy agents and toxicities, identify and manage clinically significant uncommon toxicities, and determine optimal sequencing of immunotherapies in relapsed and/or refractory disease, among other learning outcomes.
Faculty will engage attendees through a combination of case presentations with a “virtual tumor board” discussion and Q&A with diverse sub-specialty experts based on the needs of each particular case. This high-level webinar is designed so attendees will be able to execute the use of immunotherapy with increased confidence, plan management strategies for difficult cases, and identify and discuss areas of controversy in the immunotherapy field. This webinar is not accredited.
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com